Targeting the Oncogenic Tyrosine Kinase NPM-ALK in Lymphoma: The Role of Murine Models in Defining Pathogenesis and Treatment Options

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Oncogenic tyrosine kinases play a ever growing role in the pathogenesis of human malignancies. In human non-hodgkin lymphomas, the NPM-ALK oncogene arising from the t(2;5) chromosomal translocation represents the most important oncogenic tyrosine kinase identified so far. The ALK-kinase is constitutively activated by NPM-induced dimerization and signals through a multitude of growth promoting and antiapoptotic pathways. Murine models have made a significant impact on the elucidation of the molecular pathogenesis and new treatment options of malignant diseases. Here, the latest developments in the analysis of NPM-ALK induced lymphomagenesis by murine models is reviewed.





Keywords: CD 30; NPM ALK-protein expression; malignancy; oncoprotein; xenograft model

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/138945006778559229

Affiliations: Department of Internal Medicine III, Technical University of Munich, Trogerstr. 32, D-81675 Munich,Germany.

Publication date: October 1, 2006

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more